Nava Almog

4.1k citations

36 papers · 2.6k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 2%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics

Papers in

Cancer Research 16
- Cancer, Hypoxia, and Metabolism 7
- Cancer Genomics and Diagnostics 5
- Cancer-related molecular mechanisms research 4
Oncology 21
- Cancer-related Molecular Pathways 10
- Cancer Cells and Metastasis 5
- Inflammatory Biomarkers in Disease Prognosis 4

Co-authors: Varda Rotter Judah Folkman Elise R. Bender Lynn Hlatky Nathan Fowler Maria Tsiper Ravshan Ataullakhanov Felix Frenkel
Journals: Oncogene (5 papers)Blood (4 papers)Advances in experimental medicine and biology (2 papers)The FASEB Journal (2 papers)Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2 papers)
Partner nations: United States Israel Germany

In The Last Decade

Nava Almog

34 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy 2021 · 700 citations

Peers

Countries citing papers authored by Nava Almog

Since Specialization

Citations

This map shows the geographic impact of Nava Almog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nava Almog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nava Almog more than expected).

Fields of papers citing papers by Nava Almog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nava Almog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nava Almog. The network helps show where Nava Almog may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nava Almog, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nava Almog Line = papers co-authored together Nava Almog links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types. Journal of Clinical Oncology ·Pashtoon Murtaza Kasi, D. Sukhonos, V. T. MEDVETSKlI, Ruhar Singh, Nava Almog, Gesandten Gottes -Prophetie, Clinton Yam, Julio A. Peguero, Luz Priscilla Robles Rojas, Daniel Kerr, Nathan Fowler	2023	1
2	A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement Clinical Lung Cancer ·Ministère des Ressources naturelles et de la Faune du Québec, Prach Ponlawat, Sun Chuan-w, Nava Almog, Brian M. Alexander, Małgorzata Kolenkiewicz, Ken Y. Yoneda, Siraj M. Ali, Alexander D. Borowsky, Jonathan W. Riess	2022	0
3	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy Cancer Cell ·Alexander Bagaev, Nikita Kotlov, Krystle Nomie, Viktor Svekolkin, Azamat Gafurov, Olga I. Isaeva, Detra McCarty, И. Г. Козлов, Felix Frenkel, Olga Gancharova, Nava Almog, Maria Tsiper, Ravshan Ataullakhanov, Nathan Fowler Hit paper breakdown →	2021	700
4	P3.13-26 Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board Journal of Thoracic Oncology ·L.W. Chu, Karen Kelly, David R. Gandara, Primo N. Lara, Alexander D. Borowsky, Frederick J. Meyers, John D. McPherson, Rodrigo Erlich, Nava Almog, Alexa B. Schrock, S. Ali, Amir E. Sarabadani Tafreshi, 王莫非, Andreas Heilmann, Jonathan W. Riess	2018	1
5	Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas Annals of Oncology ·Jeffrey S. Ross, Pierre Vanden Borre, Nava Almog, Alexa B. Schrock, Jon Chung, J. Kubĕnka, P. Van Hove, 孝一中島, Eric A. Severson, Davide Lucantoni, Siraj M. Ali, V.A. Miller, Phil Stephens, Richard Croft, Francisco López Bustos	2017	6
6	Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells Current Pharmaceutical Design ·Yuval Shaked, Sandra S. McAllister, Ofer Fainaru, Nava Almog	2014	21
7	Consensus Micro RNAs Governing the Switch of Dormant Tumors to the Fast-Growing Angiogenic Phenotype PLoS ONE ·Nava Almog, Lili Ma, Christian Schwager, Bastian G. Brinkmann, Afshin Beheshti, Peter Vajkoczy, Judah Folkman, Lynn Hlatky, Amir Abdollahi	2012	53
8	Prospective Identification of Glioblastoma Cells Generating Dormant Tumors PLoS ONE ·Ronit Satchi‐Fainaro, Shiran Ferber, Ehud Segal, Lili Ma, Tian Yalan, Shukurov Ikrom Abdurashitovich, Lynn Hlatky, Amir Abdollahi, Nava Almog	2012	27
9	Genes and Regulatory Pathways Involved in Persistence of Dormant Micro-tumors Advances in experimental medicine and biology ·Nava Almog	2012	5
10	Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype Cancer Research ·Nava Almog, Lili Ma, Raktima Raychowdhury, Christian Schwager, Ralf Erber, Sarah Short, Lynn Hlatky, Peter Vajkoczy, Peter E. Huber, Judah Folkman, Amir Abdollahi	2009	192
11	A Model of Human Tumor Dormancy: An Angiogenic Switch From the Nonangiogenic Phenotype JNCI Journal of the National Cancer Institute ·George N. Naumov, Elise R. Bender, David Zurakowski, Soo-Young Kang, David A. Sampson, Evelyn Flynn, Randolph S. Watnick, Oddbjørn Straume, Lars A. Akslen, Judah Folkman, Nava Almog	2006	308
12	The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis Oncogene ·Alex Sigal, Devorah Matas, Nava Almog, Naomi Goldfinger, Varda Rotter	2001	15
13	The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop Carcinogenesis ·Nava Almog	2001	6
14	p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53 Oncogene ·Nava Almog, Naomi Goldfinger, Varda Rotter	2000	27
15	Epithelial Cells of Different Organs Exhibit Distinct Patterns of p53-Dependent and p53-Independent Apoptosis Following DNA Insult Experimental Cell Research ·Daniela Uberti, Dov Schwartz, Nava Almog, Naomi Goldfinger, Alon Harmelin, Maurizio Memo, Varda Rotter	1999	18
16	Mutant p53 protein expression interferes with p53-independent apoptotic pathways Oncogene ·Runzhao Li, Patrick D. Sutphin, Dov Schwartz, Devorah Matas, Nava Almog, Roland Wolkowicz, Naomi Goldfinger, Huiping Pei, Miron Prokocimer, Varda Rotter	1998	118
17	The Murine C′-Terminally Alternatively Spliced Form of p53 Induces Attenuated Apoptosis in Myeloid Cells Molecular and Cellular Biology ·Nava Almog, Runzhao Li, Amnon Peled, Dov Schwartz, Roland Wolkowicz, Naomi Goldfinger, Huiping Pei, Varda Rotter	1997	24
18	Role of wild type p53 in the G2 phase: regulation of the γirradiation-induced delay and DNA repair Oncogene ·Dov Schwartz, Nava Almog, Amnon Peled, Naomi Goldfinger, Varda Rotter	1997	63
19	Involvement of p53 in cell differentiation and development Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Nava Almog, Varda Rotter	1997	138
20	Avian Sarcoma Leukemia Virus Protease Linked to the AdjacentGagPolyprotein Is Enzymatically Active Virology ·Gila Arad, Belky Sulbarán, Nava Almog, Michael Chorev, Moshe Kotler	1995	6

About Nava Almog

Nava Almog is a scholar working on Cancer Research, Oncology, Biotechnology, Modeling and Simulation and Virology, having authored 36 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (10 papers), Cancer, Hypoxia, and Metabolism (7 papers), Angiogenesis and VEGF in Cancer (7 papers), Cancer Research and Treatments (6 papers), Cancer Cells and Metastasis (5 papers), Cancer Genomics and Diagnostics (5 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (741 citations), Immunology (467 citations), Biotechnology (176 citations) and Molecular Biology (1.4k citations). Nava Almog has collaborated with scholars based in United States, Israel and Germany. Frequent co-authors include Varda Rotter, Judah Folkman, Elise R. Bender, Lynn Hlatky, Nathan Fowler, Maria Tsiper, Ravshan Ataullakhanov, Felix Frenkel, Azamat Gafurov and Olga Gancharova. Their work appears in journals such as Oncogene, Blood, Advances in experimental medicine and biology, The FASEB Journal and Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact